| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Institut National de la Sante et de la Recherche Medicale U718 and 728, Université Paris 7 Denis Diderot, Faculté de Médicine, Institut Universitaire d'Hématologie-IFR105, AP-HP, Hôpital Saint-Louis; 2 Service d'Hématologie Clinique, Hôpital Avicenne (AP-HP)/Université Paris 13; 3 Département d'Hématologie, Institut Cochin, Hôpital Cochin, Paris, France; Schools of 4 Biosciences and 5 Medicine, Cardiff University, Cardiff, United Kingdom; 6 University of California, San Francisco, California; 7 Stanford University, Stanford, California; 8 McGowan Institute of Regenerative Medicine, Pittsburgh, Pennsylvania; and 9 Department of Haematological Medicine, Guy's, King's and Saint Thomas' School of Medicine, London, United Kingdom
Requests for reprints: Rose Ann Padua, Institut Universitaire d'Hématologie-IFR105, Institut National de la Sante et de la Recherche Medicale UMR-S-718, Laboratoire d'Hématologie Paris, Paris, France. Phone: 33-1-53-72-40-72; Fax: 33-1-53-72-40-16; E-mail: padua{at}stlouis.inserm.fr.
Myelodysplastic syndromes (MDS) are clonal stem cell hematologic disorders that evolve to acute myeloid leukemia (AML) and thus model multistep leukemogenesis. Activating RAS mutations and overexpression of BCL-2 are prognostic features of MDS/AML transformation. Using NRASD12 and BCL-2, we created two distinct models of MDS and AML, where human (h)BCL-2 is conditionally or constitutively expressed. Our novel transplantable in vivo models show that expression of hBCL-2 in a primitive compartment by mouse mammary tumor virus–long terminal repeat results in a disease resembling human MDS, whereas the myeloid MRP8 promoter induces a disease with characteristics of human AML. Expanded leukemic stem cell (Lin–/Sca-1+/c-Kit+) populations and hBCL-2 in the increased RAS-GTP complex within the expanded Sca-1+ compartment are described in both MDS/AML–like diseases. Furthermore, the oncogenic compartmentalizations provide the proapoptotic versus antiapoptotic mechanisms, by activating extracellular signal-regulated kinase and AKT signaling, in determination of the neoplastic phenotype. When hBCL-2 is switched off with doxycycline in the MDS mice, partial reversal of the phenotype was observed with persistence of bone marrow blasts and tissue infiltration as RAS recruits endogenous mouse (m)BCL-2 to remain active, thus demonstrating the role of the complex in the disease. This represents the first in vivo progression model of MDS/AML dependent on the formation of a BCL-2:RAS-GTP complex. The colocalization of BCL-2 and RAS in the bone marrow of MDS/AML patients offers targeting either oncogene as a therapeutic strategy. [Cancer Res 2007;67(24):11657–67]
This article has been cited by other articles:
![]() |
A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] |
||||
![]() |
X. Wang, K. Belguise, C. F. O'Neill, N. Sanchez-Morgan, M. Romagnoli, S. F. Eddy, N. D. Mineva, Z. Yu, C. Min, V. Trinkaus-Randall, et al. RelB NF-{kappa}B Represses Estrogen Receptor {alpha} Expression via Induction of the Zinc Finger Protein Blimp1 Mol. Cell. Biol., July 15, 2009; 29(14): 3832 - 3844. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Heuser, D. B. Yap, M. Leung, T. R. de Algara, A. Tafech, S. McKinney, J. Dixon, R. Thresher, B. Colledge, M. Carlton, et al. Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation Blood, February 12, 2009; 113(7): 1432 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-I. Kim, I. Matise, M. D. Diers, and D. A. Largaespada RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia Blood, January 29, 2009; 113(5): 1086 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fontenay and E. Gyan Apoptotic pathways to death in myelodysplastic syndromes Haematologica, September 1, 2008; 93(9): 1288 - 1292. [Full Text] [PDF] |
||||
![]() |
S. D. Nimer MDS: A Stem Cell Disorder--But What Exactly Is Wrong with the Primitive Hematopoietic Cells in This Disease? Hematology, January 1, 2008; 2008(1): 43 - 51. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |